Issue 27 of Multiple Myeloma Research Review Highlights include: Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of...
Day: 28 August 2018
CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsena
CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several...
PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma
Previous studies have suggested that the progression of SMM to symptomatic multiple myeloma (MM) may be mediated by the immune system; reinforcing...
Once-Weekly Carfilzomib Submitted for FDA Approval in Myeloma
FDA approval is being sought for a once-weekly dosing option of carfilzomib (Kyprolis) for use in combination with dexamethasone as a treatment for...
Immune Approaches Hold Great Promise in Myeloma, Expert Says
Over the past 5 years, several therapies have been developed that have proven to be effective for patients with multiple myeloma. The FDA has...